Delivra Health Brands Inc.

(Formerly Harvest One Cannabis Inc.)

Condensed Consolidated Interim Financial Statements
(Unaudited)

For the three months ended September 30, 2022 and 2021
(in Canadian dollars)

Delivra Health Brands Inc. (Formerly Harvest One Cannabis Inc.)

Table of contents

Notice to reader

The accompanying unaudited condensed interim consolidated financial statements of the Company have been prepared by and are the responsibility of the Company's management. The Company's independent auditor has not performed a review of these financial statements in accordance with the standards established by the Canadian Institute of Professional Chartered Accountants for a review of interim financial statements by an entity's auditor.

Delivra Health Brands Inc. (Formerly Harvest One Cannabis Inc.)

Condensed consolidated interim statements of financial position

As at September 30, 2022 and June 30, 2022

(Unaudited – Expressed in thousands of Canadian dollars, except share and per share amounts)

	Note	**September 30 2022**	June 30 2022
		$	$
Assets			
Current assets			
Cash		**1,246**	1,084
Accounts receivable	3	**1,434**	1,576
Short term investments	4	**24**	26
Lease receivable		**139**	134
Inventories	5	**2,226**	2,220
Prepaid expenses and deposits		**97**	104
Assets held for sale	6	**2,341**	2,341
		7,507	7,485
Lease receivable		**118**	155
Property, plant and equipment	6	**241**	270
Intangible assets	7	**3,361**	3,675
Total assets		**11,227**	11,585
Liabilities			
Current liabilities			
Accounts payable and accrued liabilities	8	**6,249**	6,105
Loans and lease liabilities	9	**463**	436
		6,712	6,541
Loans and lease liabilities	9	**1,410**	1,671
Total liabilities		**8,122**	8,212
Equity			
Share capital	11	**148,226**	148,226
Other reserves	12	**25,272**	25,234
Accumulated other comprehensive loss		**(158)**	(233)
Accumulated deficit		**(170,235)**	(169,854)
Total equity		**3,105**	3,373
Total liabilities and equity		**11,227**	11,585

Going concern (note 2(c))
Commitments and contingencies (note 15)
Subsequent event (note 17)

"Jason Bednar"
Jason Bednar, Director

"Gord Davey"
Gord Davey, Director

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Delivra Health Brands Inc. (Formerly Harvest One Cannabis Inc.)

Condensed consolidated interim statements of loss and comprehensive loss

For the three months ended September 30, 2022 and 2021

(Unaudited – Expressed in thousands of Canadian dollars, except share and per share amounts)

	Note	For the three months ended September 30	
		2022	**2021**
			$
Revenue		**1,762**	2,159
Excise taxes		**33**	29
Net revenue	14	**1,729**	2,130
Inventory expensed to cost of sales		**840**	1,421
Inventory write-down		**10**	-
Gross (loss) profit		**879**	709
Expenses			
General and administration	10	**964**	1,075
Sales and marketing		**79**	412
Depreciation and amortization	6	**332**	537
Share-based compensation	12	**38**	149
		1,413	2,173
Loss from operations		**(534)**	(1,464)
Other (expense) income			
Interest and finance costs		**161**	(10)
Loss on assets disposal	3,6	**(11)**	(67)
Gain from contingency debt settlement and other refunds	15	**-**	244
Unrealized loss/gain on short term investment	4	**(2)**	(144)
Foreign exchange gain		**5**	(13)
		153	10
Net loss from continuing operations		**(381)**	(1,454)
Other comprehensive loss			
Foreign currency translation		**75**	29
Comprehensive loss		**(306)**	(1,425)
Net loss per share – basic and diluted		**(0.002)**	(0.01)
Weighted average number of outstanding common shares		**252,617,854**	252,617,854

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Delivra Health Brands Inc. (Formerly Harvest One Cannabis Inc.)

Condensed consolidated interim statements of changes in equity

For the three months ended September 30, 2022 and 2021

(Unaudited – Expressed in thousands of Canadian dollars, except share and per share amounts)

	Note	Number of shares	Share capital	Other reserves	Accumulated other comprehensive loss	Accumulated deficit	Non-controlling interest	Total
		#	$	$	$	$	$	$
Balance, June 30, 2021		252,617,854	148,226	24,882	(286)	(162,845)	-	9,977
Share-based compensation	12	-	-	149	-	-	-	149
Foreign currency translation		-	-	-	29	-	-	29
Net loss		-	-	-	-	(1,454)	-	(1,454)
Balance, September 30, 2021		**252,617,854**	**148,226**	**25,031**	**(257)**	**(164,299)**	**-**	**8,701**
Balance, June 30, 2022		252,617,854	148,226	25,234	(233)	(169,854)	-	3,373
Share-based compensation	12	-	-	38	-	-	-	38
Foreign currency translation		-	-	-	75	-	-	75
Net loss		-	-	-	-	(381)	-	(381)
Balance, September 30, 2022		**252,617,854**	**148,226**	**25,272**	**(158)**	**(170,235)**	**-**	**3,105**

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

(Unaudited – Expressed in thousands of Canadian dollars, except share and per share amounts)

		For the three months ended September 30	
	Note	2022	2021
			$
Operating activities			
Net loss		**(381)**	(1,454)
Adjustments to reconcile non-cash items		**-**	-
Depreciation and amortization	6,7	**332**	537
Inventory write-down	5	**10**	-
Unrealized loss on fair valuation of investment	4	**2**	144
Share-based compensation	12	**38**	149
Loss on disposal of assets	3,6	**11**	67
Interest and accretion on loans and borrowings	9	**(175)**	(4)
Changes in working capital			
Accounts and lease receivable		**173**	13
Inventories		**(16)**	(36)
Prepaid expenses and deposits		**7**	16
Accounts payable and accrued liabilities		**155**	(403)
Net cash used in operating activities		**156**	(971)
Investing activities			
Purchase of property, plant and equipment		**-**	(4)
Proceeds from sale of property, plant and equipment	6	**-**	104
Purchase of intangibles		**-**	(8)
Proceeds from Cann Group shares	3	**-**	719
Net cash provided by investing activities		**-**	811
Financing activities			
Repayment of loans and borrowings	9	**(69)**	(74)
Net cash used in financing activities		**(69)**	(74)
Effect of foreign exchange on cash		**75**	29
Change in cash during the period		**162**	(205)
Cash, beginning of the year		**1,084**	4,431
Cash, end of the period		**1,246**	4,226

Supplemental information:

1) During the three months ended September 30, 2022, the interest paid on lease liabilities was $10 (2021: $14)
2) During the three months ended September 30, 2022, the interest received on lease receivables was $10 (2021: $14)

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

1. Nature of operations

Delivra Health Brands Inc. (formerly Harvest One Cannabis Inc.) ("Delivra Health" or the "Company") is a publicly traded corporation, incorporated in Canada, with its head office located at 404 – 999 Canada Place, Vancouver, BC, V6C 3E1. Delivra Health's common shares are listed on the TSX Venture Exchange (the "TSXV") under the symbol "DHB" and on the OTCQX® Best Market operated by OTC Market Group under the symbol "DHBUF". The Company was formerly known as Harvest One Cannabis Inc. and was listed on the TSXV under the symbol "HVT" and on the OTCQX® Best Market operated by OTC Market Group under the symbol "HRVOF". The name change was approved by the TSXV in September 2022.

These unaudited condensed consolidated interim financial statements as at and for the three months ended September 30, 2022 and 2021 include Delivra Health and its subsidiaries (together referred to as "the Company").

The Company's cultivation as well as medical and nutraceutical businesses were sold during the year ended June 30, 2021. Both were presented within discontinued operations during the year ended June 30, 2021. The only remaining principal activities of the Company are to provide innovative lifestyle and health and wellness products to consumers and patients in regulated markets around the world through its subsidiaries: Dream Water Global ("Dream Water") and Delivra Corp. ("Delivra").

2. Significant accounting policies

a) *Basis of presentation*

These condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standards ("IAS") 34 - Interim Financial Reporting, following the same accounting policies and methods of application as those disclosed in the annual audited consolidated financial statements for the year ended June 30, 2022 other than those disclosed in note 2(f). These condensed consolidated interim financial statements should be read in conjunction with the annual audited consolidated financial statements of the Company for the year ended June 30, 2022, which have been prepared in accordance with International Financial Reporting Standards ("IFRS").

These condensed consolidated interim financial statements were approved and authorized for issue by the Board of Directors of the Company on November 28, 2022.

b) *COVID-19 Estimation Uncertainty*

In March 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. Government measures to limit the spread of COVID-19, including the closure of non-essential businesses.

To date, the Company has not experienced a significant downturn in demand for its products in connection with the pandemic, nor has it experienced any failure to secure critical supplies or services. However, travel restrictions have impacted the overall performance of the Company. Due to the ongoing uncertainty around the pandemic, the Company cannot provide assurance that there will not be disruptions to its operations in the future.

c) *Basis of accounting – going concern*

These condensed consolidated interim financial statements have been prepared on a going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business.

The Company's ability to continue in the normal course of operations is dependent on its ability to achieve profitable operation, raise additional capital through debt or equity financings, and/or divestiture of non-core assets. While the Company has been successful in raising capital in the past, there is no assurance it will be successful in closing further financing transactions in the future.

The Company had a consolidated net loss of $381 and generated operating cash flows of $156 for the three months ended September 30, 2022 and an accumulated deficit of $170,235 as at September 30, 2022. These conditions indicate the existence of material uncertainties that may cast significant doubt on the Company's ability to continue as a going concern. If for any reason the Company is unable to continue as a going concern, then this could have an impact on the Company's ability to realize assets at their recognized values, in particular intangible assets, and to extinguish liabilities in the normal course of business at the amounts stated in the consolidated financial statements. Management acknowledges that in the absence of securing additional capital there is uncertainty over the Company's ability to meet its funding requirements as they fall due.

d) *Basis of measurement*

These condensed consolidated interim financial statements are presented in Canadian dollars and are prepared on a historical cost basis, except for certain financial instruments which are measured at fair value.

(Unaudited – Expressed in thousands of Canadian dollars, except share and per share amounts)

2. Significant accounting policies (continued)

e) *Basis of consolidation*

These condensed consolidated interim financial statements incorporate the financial statements of the Company and its subsidiaries. The accounts of the subsidiaries are prepared for the same reporting period as the Company, using consistent accounting policies. Intercompany transactions, balances and unrealized gains or losses on transactions are eliminated.

Subsidiary	Jurisdiction	% ownership	Accounting method
Dream Products Inc.	Canada	100%	Consolidation
Dream Products USA Inc.	USA	100%	Consolidation
Sarpes Beverages, LLC	USA	100%	Consolidation
Delivra Corp.	Canada	100%	Consolidation
Delivra Inc.	Canada	100%	Consolidation
Delivra Pharmaceuticals Inc.	Canada	100%	Consolidation
LivCorp Inc.	Canada	100%	Consolidation
LivCorp International Inc.	Canada	100%	Consolidation
LivVet Inc.	Canada	100%	Consolidation
PortaPack Ltd.	Canada	100%	Consolidation
United Greeneries Holdings Ltd.	Canada	100%	Consolidation
United Greeneries Operations Ltd.	Canada	100%	Consolidation

f) *New accounting policy adopted*

The Company has adopted the following new or amended IFRS standards for the period beginning July 1, 2022 with no impact on the preparation of the condensed consolidated interim financial statements:

IAS 16, Property, Plant and Equipment: This standard has been amended to prohibit an entity from deducting from the cost of an item of property, plant and equipment any proceeds received from selling items produced while the entity is preparing the asset for its intended use, clarify that an entity is "testing whether the asset is functioning properly" when it assesses the technical and physical performance of the asset and require certain related disclosures. The amendments are effective for annual periods beginning on or after January 1, 2022. The adoption of this new standard has no impact on the amounts recognized in the Company's condensed consolidated financial statements.

IAS 37, Provisions: This standard has been amended to clarify that, before a separate provision for an onerous contract is established, an entity recognizes an impairment loss that has occurred on assets used in fulfilling the contract, rather than on assets dedicated to that contract and to clarify the meaning of costs to fulfill a contract. The amendments are effective for annual periods beginning on or after January 1, 2022. The adoption of this new standard has no impact on the amounts recognized in the Company's condensed consolidated financial statements.

(Unaudited – Expressed in thousands of Canadian dollars, except share and per share amounts)

3. Accounts receivable

The summary of the Company's accounts receivable is as follows:

	September 30 2022	June 30 2022
	$	$
Trade receivables	**1,221**	1,377
Other receivables	**72**	50
Taxes recoverable from governments	**141**	149
	1,434	1,576

The Company provides credit to its customers in the normal course of business and has mitigated this risk by managing and monitoring the underlying business relationships. At the reporting date, the Company assessed the collectability of the balance and concluded that none of the receivables were uncollectible.

4. Short term investments

The Company's short term investments is composed of by the Cann Group shares received relating to the sale of the Company's wholly owned subsidiaries Satipharm Limited, Satipharm AG and Phytotech Therapeutics Ltd. (collectively, the "Satipharm Entities"), the shares are valued at the closing share price at the end of the reporting period.

The continuity of the Company's short term investments is as follows:

Balance, June 30, 2021	711
Additions	731
Disposal of shares, net of brokerage fees	(1,268)
Realized loss on disposal	(637)
Unrealized gain on changes in fair value	486
Unrealized loss on foreign exchange	3
Balance, June 30, 2022	26
Unrealized loss on changes in fair value	(2)
Balance, September 30, 2022	**24**

(Unaudited – Expressed in thousands of Canadian dollars, except share and per share amounts)

5. Inventories

The summary of the Company's inventories is as follows:

	September 30 2022	June 30 2022
	$	$
Infused licensed products		
Raw materials and work-in-progress	**30**	126
Finished goods	**27**	111
	57	237
Liquid sleep shots and sleep powder packets		
Finished goods	**949**	904
	949	904
Pain relief creams		
Raw materials and work-in-progress	**742**	565
Finished goods	**343**	452
	1,085	1,017
Packaging and supplies	**332**	259
Inventory allowance	**(197)**	(197)
	2,226	2,220

a) *Infused licensed products*

Infused licensed products on hand as at September 30, 2022 pertains to infused 2.0 products produced and held by the Company's manufacturer/distributor.

b) *Allowance and write-downs*

During the three months ended September 30, 2022, the inventory write-down was $10 (2021: nil). Due to estimation uncertainties attributable to forecasting including slow moving and expiry dates, it is not possible to predict whether the full carrying value of inventory can be recognized in the next 12 months. As such, as at September 30, 2022, the Company recognized an inventory valuation allowance of $197.

6. Property, plant and equipment

The summary of the Company's property, plant and equipment is as follows:

	Plant and equipment	Office equipment	Construction in progress(i)	Right-of-use assets	Total
	$	$	$	$	$
Cost					
July 1, 2021	480	342	2,511	154	3,487
Additions	-	10	-	-	10
Transfers to assets held for sale	-	-	(2,341)	-	(2,341)
Disposals and write-downs	-	-	(159)	-	(159)
June 30, 2022	480	352	11	154	997

(Unaudited – Expressed in thousands of Canadian dollars, except share and per share amounts)

6. Property, plant and equipment (Continued)

	Plant and equipment	Office equipment	Construction in progress(i)	Right-of-use assets	Total
Accumulated depreciation					
July 1, 2021	153	284	-	142	579
Depreciation	76	60	-	12	148
June 30, 2022	229	344	-	154	727
Net book value June 30, 2022	251	8	11	-	270
Cost					
July 1, 2022	480	352	11	154	997
Additions	-	-	-	-	-
Disposal	-	-	(11)	-	(11)
September 30, 2022	480	352	-	154	986
Accumulated depreciation					
July 1, 2022	229	344	-	154	727
Depreciation	17	1	-	-	18
September 30, 2022	246	345	-	154	745
Net book value September 30, 2022	**234**	**7**	**-**	**-**	**241**

i) Construction in progress mainly relates to the construction of a 68,000 square foot indoor flowering facility (the "Lucky Lake Facility") at the Lucky Lake property in Saskatchewan. The Company has suspended active development of its Lucky Lake Facility since the beginning of the Company's strategic review of alternatives in February 2020 (the "Strategic Review") and continues to evaluate all strategic alternatives. During the year ended June 30, 2022, the Company decided to sell the Lucky Lake Facility. The property is marketed through a real estate agent in Saskatchewan and is available for an immediate sale in its present condition and the sale is highly probable and expected to be completed within 12 months therefore, this asset has been classified as assets held for sale in the amount of $2,341.

During the three months ended September 30, 2022, the company disposed of a technology project under the construction in progress with a loss of $11. During the three months ended September 30, 2021, the Company disposed $159 of capitalized costs under construction in process and received $104 proceeds from the disposal with a $55 loss on disposal.

(Unaudited – Expressed in thousands of Canadian dollars, except share and per share amounts)

7. Intangible assets

The summary of the Company's intangible assets is as follows:

	Brand names	Technology & formulations	In-process R&D	Customer relationships	Website &other	Total
Cost	$	$	$	$	$	$
July 1, 2021	6,043	2,154	398	1,540	123	10,258
Additions	-	-	-	-	12	12
Disposals and write-downs	-	-	(398)	-	-	(398)
June 30, 2022	6,043	2,154	-	1,540	135	9,872
Accumulated amortization						
July 1, 2021	2,014	1,463	-	679	70	4,226
Amortization	1,007	691	-	237	36	1,971
June 30, 2022	3,021	2,154	-	916	106	6,197
Net book value June 30, 2022	3,022	-	-	624	28	3,675
Cost						
July 1, 2022	6,043	2,154	-	1,540	135	9,872
Additions	-	-	-	-	-	-
September 30, 2022	6,043	2,154	-	1,540	135	9,872
Accumulated amortization						
July 1, 2022	3,021	2,154	-	916	106	6,197
Amortization	250	-	-	55	9	314
September 30, 2022	3,271	2,154	-	971	115	6,511
Net book value September 30, 2022	**2,772**	**-**	**-**	**569**	**20**	**3,361**

8. Accounts payable and accrued liabilities

The summary of the Company's accounts payable and accrued liabilities is as follows:

	September 30 2022	June 30 2022
	$	$
Trade payables	**3,490**	3,584
Accrued liabilities	**1,869**	1,744
Payroll liabilities	**175**	186
Other payables	**715**	591
	6,249	6,105

Trade payables, accrued liabilities, payroll liabilities and other payables are non-interest bearing. All amounts are expected to be settled within 12 months.

(Unaudited – Expressed in thousands of Canadian dollars, except share and per share amounts)

9. Loans and lease liabilities

The summary of the Company's loans and borrowings is as follows:

	Notes	**September 30 2022**	June 30 2022
		$	$
Secured and unsecured loans	(a)	1,616	1,819
Lease liabilities	(b)	257	288
Total loans and lease liabilities		1,873	2,107
Current portion		(463)	(436)
Non-current portion		1,410	1,671

a) *Secured and unsecured loans*

In connection with the Delivra acquisition on July 3, 2019, the Company assumed eight unsecured loans from the Atlantic Canada Opportunities Agency ("ACOA") and one secured loan from Finance PEI. The loan with Finance PEI are secured by a registered General Security Agreement conveying an interest in all personal property of the Company's subsidiary, LivCorp Inc., and a limited guarantee by Delivra Inc. to a maximum of the principal amount of debt outstanding together with accrued interest, this loan has been fully paid off during the year ended June 30, 2021. The summary of the secured and unsecured loans assumed is as follows:

	Effective Interest Rate(ii)	Maturity	Face Value	Balance, July 1, 2022	Accretion	Repayments	**Total**
			$	$	$	$	**$**
Loans assumed on acquisition							
ACOA 201210	16%	(i)	2,860	1,239	(134)	**-**	**1,105**
ACOA 202454	16%	2023	85	10	-	(7)	**3**
ACOA 203110	16%	2024	197	87	3	(10)	**80**
ACOA 206091	16%	2023	76	21	1	(6)	**16**
ACOA 206924	16%	2026	117	51	2	(5)	**48**
ACOA 207593	16%	(i)	484	411	(47)	-	**364**
Balance, September 30, 2021			3,819	1,819	(175)	(28)	**1,616**

(i) The annual instalments are calculated as 5% to 10% of forecasted revenues from pipeline products for the calendar year immediately preceding the due date of the respective payment, with an estimated commencement date of August 31, 2023 to August 31, 2024.

(ii) The discount rate used to calculate the fair value of the loans

The loans with ACOA are through the Atlantic Innovation Fund for the specified projects, in which repayable contributions are received by the Company to a maximum amount based on the lesser of: (i) a percentage of eligible costs, plus a percentage of working capital requirements for the project in certain instances, and (ii) a specified amount. The Company must meet certain conditions of assistance, which are specific to each agreement and project, including maintaining specified amounts of equity.

(Unaudited – Expressed in thousands of Canadian dollars, except share and per share amounts)

9. Loans and lease liabilities (continued)

b) *Lease liabilities*

The continuity of the Company's lease liabilities is as follows:

Balance, June 30, 2021	418
Interest expense on lease liabilities	49
Lease payments	(179)
Balance, June 30, 2022	288
Interest expense on lease liabilities	10
Lease payments	(41)
Balance, September 30, 2021	257
Current portion	(139)
Non-current portion	118

For the period ended September 30, 2022, the Company recorded $(7) rent expense recovery due to annual adjustment relating to short term leases.

10. General and administration expenses

The summary of the Company's general and administration expenses is as follows:

	September 30 2022	September 30 2021
	$	$
Insurance	**42**	**43**
Investor relations	**20**	**19**
Office and general	**117**	**110**
Professional and consulting services	**199**	**239**
Regulatory	**3**	**3**
Rent	**(7)**	**2**
Salaries, bonus and benefits	**580**	**651**
Travel	**10**	**8**
	964	**1,075**

11. Share capital

a) *Authorized*

The Company has an unlimited number of authorized common shares with no par value.

b) *Issued capital*

At September 30, 2022, 252,617,854 common shares (June 30, 2022 – 252,617,854) were issued and fully paid.

(Unaudited – Expressed in thousands of Canadian dollars, except share and per share amounts)

12. Other reserves

The summary of the Company's other reserves is as follows:

	Share-based awards (a)	Warrants (b)	Other	Total
	$	$	$	$
Balance, June 30, 2021	11,426	12,641	815	24,882
Warrants issued	-	16	-	16
Share-based compensation	336	-	-	336
Balance, June 30, 2022	11,762	12,658	815	25,234
Share-based compensation	38	-	-	38
Balance, September, 2022	**11,800**	**12,658**	**815**	**25,272**

a) *Share-based awards*

(i) Stock options

The Company has established a share purchase option plan ("Plan") whereby the Company's Board of Directors may from time to time grant stock options to employees and non-employees. Options granted under the Plan will not have a term to exceed 5 years from the date of grant. The maximum number of shares that may be reserved for issuance under the Plan is 21,507,948. Vesting is determined by the Board of Directors.

The continuity of the Company's stock options is as follows:

	Number outstanding	Weighted average exercise price
	#	$
Outstanding at June 30, 2021	18,479,112	0.31
Expired	(1,677,319)	0.91
Forfeited	(1,598,652)	0.32
Outstanding at June 30, 2022	**15,203,141**	**0.24**
Granted	-	-
Forfeited	(25,000)	0.12
Outstanding at September 30, 2022	**15,178,141**	**0.24**

During the three months ended September 30, 2022 and 2021, there were no new stock options granted.

The number of options outstanding and exercisable at September 30, 2022 is as follows:

Expiry date	Number of stock options outstanding	Exercise price	Number of stock options exercisable
	#	$	#
January 24, 2023	877,625	0.76	877,625
September 18, 2023	700,000	0.91	700,000
October 12, 2023	297,500	0.61	297,500
April 22, 2024	775,000	0.85	823,333
June 17, 2024	150,000	0.68	150,000
July 31, 2024	300,000	0.56	300,000
September 4, 2024	44,444	0.52	50,000
July 14, 2025	4,795,001	0.09	5,169,999
December 7, 2025	1,500,000	0.08	875,000
April 8, 2026	5,738,571	0.12	4,649,682
	15,178,141		**13,893,139**

(Unaudited – Expressed in thousands of Canadian dollars, except share and per share amounts)

12. Other reserves (continued)

b) *Warrants*

The continuity of the Company's warrants is as follows:

	Brokers' RTO Warrants, Secondary Warrants	Debenture Warrants	Dream Water Warrants	Jonathan Carroll Warrants(i)	Hygrovest * Warrants	Bought Deal Warrants	Total number outstanding	Weighted average exercise price
							#	$
Outstanding at June 30, 2021	100,002	-	-	-	17,083,333	37,096,700	54,280,035	0.15
Issued	-	-	-	300,000	-	-	300,000	0.09
Expired	(100,002)				(17,083,333)		(17,183,335)	0.07
Outstanding at June 30, 2022	-	-	-	300,000	-	37,096,700	37,396,700	0.19
Outstanding at September 30, 2022	**-**	**-**	**-**	**300,000**	**-**	**37,096,700**	**37,396,700**	**0.19**

*MMJ Group Holdings Limited changed the company name to Hygrovest Limited on December 22, 2021.

(i) Jonathan Carroll Warrants

On July 26, 2021, the Company announced that it engaged an arm's length service provider, Jonathan Carroll (the "Consultant") to provide strategic advisory and consulting services to the Company (the "Consulting Services") for a 24-month period. As partial consideration for the Consulting Services, the Company agreed to grant an aggregate of 1,500,000 common share purchase warrants (the "Consultant Warrants") to the Consultant in accordance with the provisions of the consulting agreement. On September 27, 2021, the Company issued 300,000 Consultant Warrants. Each Consultant Warrant will entitle the holder to purchase one common share at a price of $0.09 per share with an expiry date of September 27, 2023. The fair value of the Consultant Warrants in the amount of $16 was estimated using the following assumptions:

Risk-free interest rate	0.50 %
Expected life of warrants (years)	1.99
Expected annualized volatility	149.13 %
Expected dividend yield	Nil

The Company's outstanding warrants as of September 30, 2022 is as follows:

	Issued	Outstanding	Exercise price	Expiry date
	#	#	$	
Bought Deal Warrants	37,096,700	37,096,700	0.20	Mar 17, 2024
Jonathan Carroll Warrants	300,000	300,000	0.09	Sept 27, 2023
	37,396,700	**37,396,700**		

(Unaudited – Expressed in thousands of Canadian dollars, except share and per share amounts)

13. Related parties

The summary of the Company's related party transactions during the three months ended September 30, 2022 and 2021 is as follows:

a) *Compensation of key management personnel*

Key management personnel ("KMP") include persons having the authority and responsibility for planning, directing and controlling the activities of the Company as a whole. The KMP of the Company are the members of the Company's executive management team and Board of Directors. Compensation provided to KMP is as follows:

	September 30 2022	September 30 2021
	$	$
Salaries and benefits	**161**	161
Directors' fees	**60**	60
Share-based compensation	**22**	100
Total	**243**	321

b) *Payments to related parties*

As at September 30, 2022, there was $280 directors' fees (June 30, 2022 – $220) included in accounts payable and accrued liabilities.

14. Revenue and other geographical information

The Company generates net revenue from two geographical locations:

Net revenue	**September 30 2022**	September 30 2021
	$	$
Canada	**888**	891
US	**841**	1,239
Total	**1,729**	2,130

Net revenues in each geographical location relate to the sale of the following:

- Canada – Dream Water liquid sleep shots and sleep powder packets, and LivRelief™ pain relief creams
- US – Dream Water liquid sleep shots and sleep powder packets

The Company's non-current assets are all in Canada.

15. Commitments and contingencies

During the year ended June 30, 2020, United Greeneries Operations, a subsidiary of the Company, was named as the defendant in a civil claim (the "Claim") filed in the Supreme Court of British Columbia in respect of the termination of the lease agreement for land and property in Aldergrove, British Columbia in August 2018. The plaintiff filed a summary trial motion in March 2020 in which it seeks an order for damages for breach of the lease agreement plus court costs and statutory pre-judgment interest. In June 2020, United Greeneries Operations filed a response in defense of the Claim and filed its own summary trial motion. Management's assessment as of June 30, 2021, based on its interpretation of the agreement and independent legal advice, was that the plaintiff may be partly successful with the Claim up to $250 , subject to a set-off claim by United Greeneries Operations against the plaintiff seeking the return of a $70 deposit paid in accordance with the terms of the lease and possession of certain security and electronic equipment held by the plaintiff. The Company has accrued $250 as at June 30, 2021. In November 2021, the two parties reached an agreement to settle the entire claim in the amount of $35, which resulted in a $215 gain as a reduction in the Company's liabilities.

(Unaudited – Expressed in thousands of Canadian dollars, except share and per share amounts)

15. Commitments and contingencies (Continued)

On March 19, 2022, Kadco Electric Inc. (the ”Contractor”), a contractor of the Company’s previous cannabis business of United Greeneries Operations LTD & United Greeneries Holdings LTD. issued a statement of claim against the Company claiming, among other things, breach of trust and unjust enrichment related to unpaid debt of $163. On July 25, 2022, the Company issued a statement of defense and counterclaim of $161 against the Contractor claiming, among other things, the Company had overpaid based for services rendered based on the life to date percentage of completion of the project conducted by the Contractor. The Company believes the claim made by the Contractor against the Company lacks merit and intends to vigorously defend this matter.

On July 19, 2022, Jonathan Carroll (the “Consultant”) issued a statement of claim against the Company claiming, among other things, damages for breach of contract and exemplary damages of $134 and an order for the delivery of the balance of the unissued Consultant Warrants of 1,200,000 units. The Company did not accrue for such claims. On September 14, 2022, the Company issued a statement of defense and counterclaim of $200 against the Consultant claiming, among other things, damages for negligent misrepresentation, breach of contract and breach of its duty of good faith and honest performance of its contractual obligations. On October 21, 2022, the Consultant issued a reply and defense to the counter-claim. The Company believes the claim made by the Consultant against the Company lacks merit and intends to vigorously defend this matter.

16. Financial instruments and risk

The Company thoroughly examines the various financial instruments and risks to which it is exposed and assesses the impact and likelihood of those risks. These risks include foreign exchange risk, credit risk, interest rate risk, and liquidity risk. Where material, these risks are reviewed and monitored by the Board of Directors.

The Board of Directors has overall responsibility for the determination of the Company’s risk management objectives and policies. The overall objective of the Board is to set policies that seek to reduce risk as far as possible without unduly affecting the Company’s competitiveness and flexibility.

Foreign exchange risk

Foreign exchange risk is the risk that the fair value of future cash flows will fluctuate as a result of changes in foreign exchange rates. As at September 30, 2022, the Company is exposed to foreign currency risk through its bank accounts denominated in United States Dollars (“USD”) and Australian Dollars (“AUD”). A 10% appreciation (depreciation) of USD or AUD against the CAD, with all other variables held constant, would result in an immaterial change in the Company’s loss and comprehensive loss for the year.

Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company’s trade accounts receivable. The Company’s cash and accounts receivable are exposed to credit risk. The risk for cash is mitigated by holding these instruments with highly rated financial institutions. The Company provides credit to its customers in the normal course of business and has mitigated this risk by managing and monitoring the underlying business relationships. As at September 30, 2022, the Company is exposed to credit risk in the amount of the carrying amount of the Company’s cash and accounts receivable.

As at September 30, 2022, the Company’s aging of receivables was approximately as follows:

	September 30 2022	June 30 2022
	$	$
0 – 60 days	**1,139**	1,242
Over 60 days	**82**	135
	1,221	1,377

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. As at September 30, 2022, the Company is not exposed to any significant interest rate risk.

16. Financial instruments and risk (Continued)

Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with financial liabilities. The Company manages liquidity risk by maintaining sufficient cash balances to enable settlement of transactions on the due date. Accounts payable and accrued liabilities have maturities of 30 days or less or are due on demand and are subject to normal trade terms. The Company has current assets of $7,507 and current liabilities of $6,712. The Company addresses its liquidity through debt or equity financing obtained through the sale of convertible debentures and common shares. While the Company has been successful in securing financings in the past, there is no assurance that it will be able to do so in the future.

Fair value hierarchy

Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are:
Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities;
Level 2 – Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and
Level 3 – Inputs that are not based on observable market data.

During the period ended September 30, 2022, there were no transfers of amounts between fair value levels.

Cash and short-term investments are classified as a Level 1 financial instrument.

The Company's other financial instruments, including accounts receivable, current portion of lease receivable, promissory note and accounts payable and accrued liabilities are carried at cost which approximates fair value due to the relatively short maturity of those instruments. The carrying value of the Company's non-current portion of lease receivable, loans and borrowings approximate fair value as they bear a market rate of interest.

17. Subsequent events

The Company announced on November 2, 2022 that it has granted certain directors, officers and employees of the Company an aggregate of 4,900,000 options to purchase common shares in the capital of the Company pursuant to its share option plan. The options are exercisable at a price of $0.05 per common share and will have a term of five years from the date of grant.